nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—Vismodegib—SMO—meningioma	0.0417	1	CrCbGaD
Sorafenib—HTR2C—choroid plexus—meningioma	0.0353	0.101	CbGeAlD
Sorafenib—MAPK15—brainstem—meningioma	0.0153	0.0439	CbGeAlD
Sorafenib—MAPK15—medulla oblongata—meningioma	0.0107	0.0306	CbGeAlD
Sorafenib—HTR2C—telencephalic ventricle—meningioma	0.0103	0.0296	CbGeAlD
Sorafenib—CDKL3—brain—meningioma	0.00744	0.0213	CbGeAlD
Sorafenib—CDKL2—brain—meningioma	0.0068	0.0195	CbGeAlD
Sorafenib—MAPK15—brain—meningioma	0.00613	0.0176	CbGeAlD
Sorafenib—RAF1—brainstem—meningioma	0.00451	0.0129	CbGeAlD
Sorafenib—MAPK11—cerebellum—meningioma	0.00447	0.0128	CbGeAlD
Sorafenib—CDK7—cerebellum—meningioma	0.0044	0.0126	CbGeAlD
Sorafenib—TAOK2—cerebellum—meningioma	0.00437	0.0125	CbGeAlD
Sorafenib—HIPK4—brain—meningioma	0.00412	0.0118	CbGeAlD
Sorafenib—FGFR1—medulla oblongata—meningioma	0.00401	0.0115	CbGeAlD
Sorafenib—MAP2K5—brainstem—meningioma	0.00383	0.011	CbGeAlD
Sorafenib—ZAK—cerebellum—meningioma	0.0038	0.0109	CbGeAlD
Sorafenib—MAP3K7—medulla oblongata—meningioma	0.0038	0.0109	CbGeAlD
Sorafenib—HIPK3—cerebellum—meningioma	0.00372	0.0107	CbGeAlD
Sorafenib—MKNK2—medulla oblongata—meningioma	0.00368	0.0106	CbGeAlD
Sorafenib—MKNK1—medulla oblongata—meningioma	0.00363	0.0104	CbGeAlD
Sorafenib—MAPK11—brain—meningioma	0.00363	0.0104	CbGeAlD
Sorafenib—RET—medulla oblongata—meningioma	0.00359	0.0103	CbGeAlD
Sorafenib—FGFR1—spinal cord—meningioma	0.00358	0.0103	CbGeAlD
Sorafenib—CDK7—brain—meningioma	0.00357	0.0102	CbGeAlD
Sorafenib—TAOK2—brain—meningioma	0.00355	0.0102	CbGeAlD
Sorafenib—AURKC—brain—meningioma	0.00352	0.0101	CbGeAlD
Sorafenib—TIE1—cerebellum—meningioma	0.00348	0.00997	CbGeAlD
Sorafenib—KIT—brainstem—meningioma	0.0034	0.00974	CbGeAlD
Sorafenib—MAP3K7—spinal cord—meningioma	0.00339	0.00971	CbGeAlD
Sorafenib—BRAF—cerebellum—meningioma	0.00333	0.00956	CbGeAlD
Sorafenib—RALBP1—medulla oblongata—meningioma	0.00332	0.00953	CbGeAlD
Sorafenib—MKNK2—spinal cord—meningioma	0.00328	0.00941	CbGeAlD
Sorafenib—EPHA6—brain—meningioma	0.00326	0.00934	CbGeAlD
Sorafenib—MKNK1—spinal cord—meningioma	0.00324	0.00929	CbGeAlD
Sorafenib—RET—spinal cord—meningioma	0.0032	0.00918	CbGeAlD
Sorafenib—EPHX2—cerebellum—meningioma	0.00319	0.00914	CbGeAlD
Sorafenib—FLT3—cerebellum—meningioma	0.00316	0.00907	CbGeAlD
Sorafenib—FLT1—medulla oblongata—meningioma	0.00316	0.00906	CbGeAlD
Sorafenib—RAF1—medulla oblongata—meningioma	0.00314	0.00901	CbGeAlD
Sorafenib—EPHB6—medulla oblongata—meningioma	0.00312	0.00896	CbGeAlD
Sorafenib—ZAK—brain—meningioma	0.00309	0.00886	CbGeAlD
Sorafenib—HIPK3—brain—meningioma	0.00302	0.00867	CbGeAlD
Sorafenib—RALBP1—spinal cord—meningioma	0.00296	0.0085	CbGeAlD
Sorafenib—MAP3K19—brain—meningioma	0.00296	0.00849	CbGeAlD
Sorafenib—FGFR1—cerebellum—meningioma	0.00284	0.00813	CbGeAlD
Sorafenib—TIE1—brain—meningioma	0.00283	0.0081	CbGeAlD
Sorafenib—FLT1—spinal cord—meningioma	0.00282	0.00808	CbGeAlD
Sorafenib—RAF1—spinal cord—meningioma	0.0028	0.00804	CbGeAlD
Sorafenib—HTR2C—brainstem—meningioma	0.0028	0.00802	CbGeAlD
Sorafenib—EPHB6—spinal cord—meningioma	0.00279	0.00799	CbGeAlD
Sorafenib—BRAF—brain—meningioma	0.00271	0.00777	CbGeAlD
Sorafenib—MAP3K7—cerebellum—meningioma	0.00268	0.0077	CbGeAlD
Sorafenib—KDR—medulla oblongata—meningioma	0.00267	0.00766	CbGeAlD
Sorafenib—MAP2K5—medulla oblongata—meningioma	0.00267	0.00766	CbGeAlD
Sorafenib—PDGFRA—spinal cord—meningioma	0.00264	0.00757	CbGeAlD
Sorafenib—CSF1R—medulla oblongata—meningioma	0.00261	0.00748	CbGeAlD
Sorafenib—MKNK2—cerebellum—meningioma	0.0026	0.00746	CbGeAlD
Sorafenib—EPHX2—brain—meningioma	0.00259	0.00742	CbGeAlD
Sorafenib—MKNK1—cerebellum—meningioma	0.00257	0.00737	CbGeAlD
Sorafenib—RET—cerebellum—meningioma	0.00254	0.00728	CbGeAlD
Sorafenib—KDR—spinal cord—meningioma	0.00238	0.00683	CbGeAlD
Sorafenib—MAP2K5—spinal cord—meningioma	0.00238	0.00683	CbGeAlD
Sorafenib—KIT—medulla oblongata—meningioma	0.00237	0.00679	CbGeAlD
Sorafenib—RALBP1—cerebellum—meningioma	0.00235	0.00674	CbGeAlD
Sorafenib—FLT4—brain—meningioma	0.00233	0.00669	CbGeAlD
Sorafenib—CSF1R—spinal cord—meningioma	0.00233	0.00667	CbGeAlD
Sorafenib—PDGFRB—medulla oblongata—meningioma	0.00231	0.00663	CbGeAlD
Sorafenib—FGFR1—brain—meningioma	0.0023	0.0066	CbGeAlD
Sorafenib—FLT1—cerebellum—meningioma	0.00223	0.00641	CbGeAlD
Sorafenib—RAF1—cerebellum—meningioma	0.00222	0.00637	CbGeAlD
Sorafenib—EPHB6—cerebellum—meningioma	0.00221	0.00633	CbGeAlD
Sorafenib—MAP3K7—brain—meningioma	0.00218	0.00625	CbGeAlD
Sorafenib—STK10—cerebellum—meningioma	0.00212	0.00607	CbGeAlD
Sorafenib—MKNK2—brain—meningioma	0.00211	0.00606	CbGeAlD
Sorafenib—KIT—spinal cord—meningioma	0.00211	0.00605	CbGeAlD
Sorafenib—PDGFRA—cerebellum—meningioma	0.00209	0.00601	CbGeAlD
Sorafenib—MKNK1—brain—meningioma	0.00209	0.00598	CbGeAlD
Sorafenib—PDGFRB—spinal cord—meningioma	0.00206	0.00591	CbGeAlD
Sorafenib—RET—brain—meningioma	0.00206	0.00591	CbGeAlD
Sorafenib—HTR2C—medulla oblongata—meningioma	0.00195	0.00559	CbGeAlD
Sorafenib—RALBP1—brain—meningioma	0.00191	0.00547	CbGeAlD
Sorafenib—KDR—cerebellum—meningioma	0.00189	0.00542	CbGeAlD
Sorafenib—MAP2K5—cerebellum—meningioma	0.00189	0.00542	CbGeAlD
Sorafenib—CSF1R—cerebellum—meningioma	0.00184	0.00529	CbGeAlD
Sorafenib—FLT1—brain—meningioma	0.00182	0.00521	CbGeAlD
Sorafenib—RAF1—brain—meningioma	0.0018	0.00518	CbGeAlD
Sorafenib—EPHB6—brain—meningioma	0.00179	0.00515	CbGeAlD
Sorafenib—HTR2C—spinal cord—meningioma	0.00174	0.00499	CbGeAlD
Sorafenib—STK10—brain—meningioma	0.00172	0.00493	CbGeAlD
Sorafenib—PDGFRA—brain—meningioma	0.0017	0.00488	CbGeAlD
Sorafenib—KIT—cerebellum—meningioma	0.00167	0.0048	CbGeAlD
Sorafenib—PDGFRB—cerebellum—meningioma	0.00164	0.00469	CbGeAlD
Sorafenib—KDR—brain—meningioma	0.00153	0.0044	CbGeAlD
Sorafenib—MAP2K5—brain—meningioma	0.00153	0.0044	CbGeAlD
Sorafenib—CSF1R—brain—meningioma	0.0015	0.00429	CbGeAlD
Sorafenib—KIT—brain—meningioma	0.00136	0.0039	CbGeAlD
Sorafenib—PDGFRB—brain—meningioma	0.00133	0.00381	CbGeAlD
Sorafenib—ABCG2—medulla oblongata—meningioma	0.0013	0.00373	CbGeAlD
Sorafenib—CYP2D6—brainstem—meningioma	0.00128	0.00366	CbGeAlD
Sorafenib—ABCG2—spinal cord—meningioma	0.00116	0.00332	CbGeAlD
Sorafenib—HTR2C—brain—meningioma	0.00112	0.00321	CbGeAlD
Sorafenib—ABCC4—brain—meningioma	0.00106	0.00303	CbGeAlD
Sorafenib—HTR2B—brain—meningioma	0.00105	0.00302	CbGeAlD
Sorafenib—ABCG2—cerebellum—meningioma	0.000919	0.00264	CbGeAlD
Sorafenib—CYP2C8—brain—meningioma	0.000768	0.0022	CbGeAlD
Sorafenib—ABCG2—brain—meningioma	0.000747	0.00214	CbGeAlD
Sorafenib—CYP2B6—brain—meningioma	0.000689	0.00197	CbGeAlD
Sorafenib—ABCB1—medulla oblongata—meningioma	0.000641	0.00184	CbGeAlD
Sorafenib—CYP2D6—cerebellum—meningioma	0.00063	0.00181	CbGeAlD
Sorafenib—ABCB1—spinal cord—meningioma	0.000572	0.00164	CbGeAlD
Sorafenib—CYP2D6—brain—meningioma	0.000512	0.00147	CbGeAlD
Sorafenib—ABCB1—cerebellum—meningioma	0.000453	0.0013	CbGeAlD
Sorafenib—ABCB1—brain—meningioma	0.000368	0.00106	CbGeAlD
Sorafenib—RAF1—Developmental Biology—ERBB2—meningioma	0.00013	0.000213	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SMO—meningioma	0.000129	0.000212	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—ERBB2—meningioma	0.000129	0.000211	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—PTEN—meningioma	0.000129	0.000211	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—PTEN—meningioma	0.000129	0.000211	CbGpPWpGaD
Sorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	0.000129	0.000211	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—PTEN—meningioma	0.000128	0.00021	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HES1—meningioma	0.000128	0.00021	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—PTEN—meningioma	0.000126	0.000207	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—PDGFB—meningioma	0.000125	0.000204	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—PDGFB—meningioma	0.000124	0.000204	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PGR—meningioma	0.000124	0.000203	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—ERBB2—meningioma	0.000124	0.000203	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—PTEN—meningioma	0.000124	0.000203	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—PTEN—meningioma	0.000124	0.000203	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by NGF—AKT1—meningioma	0.000124	0.000203	CbGpPWpGaD
Sorafenib—CDK7—Disease—ERBB2—meningioma	0.000123	0.000202	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by NGF—AKT1—meningioma	0.000123	0.000202	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SMO—meningioma	0.000123	0.000202	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—ERBB2—meningioma	0.000122	0.000201	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—PTEN—meningioma	0.000122	0.000201	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—PTEN—meningioma	0.000122	0.0002	CbGpPWpGaD
Sorafenib—RAF1—Platelet activation, signaling and aggregation—AKT1—meningioma	0.000122	0.0002	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALAD—meningioma	0.000121	0.000199	CbGpPWpGaD
Sorafenib—KIT—Disease—PDGFB—meningioma	0.000121	0.000199	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HES1—meningioma	0.000121	0.000198	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling by Wnt—AKT1—meningioma	0.00012	0.000197	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALAD—meningioma	0.000118	0.000194	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PGR—meningioma	0.000118	0.000194	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—PTEN—meningioma	0.000117	0.000193	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—PTEN—meningioma	0.000117	0.000192	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TSHB—meningioma	0.000117	0.000192	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SMO—meningioma	0.000115	0.000189	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PDGFB—meningioma	0.000115	0.000189	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—ERBB2—meningioma	0.000115	0.000188	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PDGFB—meningioma	0.000115	0.000188	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PDGFB—meningioma	0.000112	0.000184	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PDGFB—meningioma	0.000112	0.000184	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.000112	0.000183	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALAD—meningioma	0.000112	0.000183	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by NGF—AKT1—meningioma	0.000111	0.000182	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALAD—meningioma	0.000111	0.000182	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PGR—meningioma	0.00011	0.000181	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—ERBB2—meningioma	0.00011	0.000181	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—ERBB2—meningioma	0.00011	0.000181	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HES1—meningioma	0.00011	0.000181	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—PTEN—meningioma	0.00011	0.00018	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PDGFB—meningioma	0.000109	0.00018	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HES1—meningioma	0.000109	0.000179	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—AKT1—meningioma	0.000108	0.000178	CbGpPWpGaD
Sorafenib—RAF1—Disease—HES1—meningioma	0.000108	0.000177	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—PTEN—meningioma	0.000106	0.000173	CbGpPWpGaD
Sorafenib—CDK7—Disease—PTEN—meningioma	0.000105	0.000172	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—PTEN—meningioma	0.000104	0.000171	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—TSHB—meningioma	0.000104	0.00017	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PDGFB—meningioma	0.000103	0.00017	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.000102	0.000167	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—TSHB—meningioma	0.000101	0.000166	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PDGFB—meningioma	9.98e-05	0.000164	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SMO—meningioma	9.94e-05	0.000163	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HES1—meningioma	9.93e-05	0.000163	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HES1—meningioma	9.93e-05	0.000163	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—AKT1—meningioma	9.9e-05	0.000162	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—PTEN—meningioma	9.79e-05	0.000161	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—ERBB2—meningioma	9.76e-05	0.00016	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PGR—meningioma	9.53e-05	0.000156	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALAD—meningioma	9.46e-05	0.000155	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HES1—meningioma	9.42e-05	0.000155	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PDGFB—meningioma	9.41e-05	0.000154	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—PTEN—meningioma	9.4e-05	0.000154	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—PTEN—meningioma	9.4e-05	0.000154	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HES1—meningioma	9.4e-05	0.000154	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PDGFB—meningioma	9.33e-05	0.000153	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—AKT1—meningioma	9.32e-05	0.000153	CbGpPWpGaD
Sorafenib—RAF1—Disease—PDGFB—meningioma	9.21e-05	0.000151	CbGpPWpGaD
Sorafenib—BRAF—Disease—ERBB2—meningioma	8.93e-05	0.000146	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—AKT1—meningioma	8.83e-05	0.000145	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TP53—meningioma	8.83e-05	0.000145	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—ERBB2—meningioma	8.8e-05	0.000144	CbGpPWpGaD
Sorafenib—KIT—Immune System—ERBB2—meningioma	8.8e-05	0.000144	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—TSHB—meningioma	8.76e-05	0.000144	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TP53—meningioma	8.74e-05	0.000143	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TP53—meningioma	8.6e-05	0.000141	CbGpPWpGaD
Sorafenib—MKNK1—Disease—AKT1—meningioma	8.6e-05	0.000141	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PDGFB—meningioma	8.49e-05	0.000139	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PDGFB—meningioma	8.49e-05	0.000139	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HES1—meningioma	8.46e-05	0.000139	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—ERBB2—meningioma	8.35e-05	0.000137	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—ERBB2—meningioma	8.33e-05	0.000137	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—PTEN—meningioma	8.32e-05	0.000137	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—AKT1—meningioma	8.24e-05	0.000135	CbGpPWpGaD
Sorafenib—KIT—Disease—ERBB2—meningioma	8.13e-05	0.000133	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HES1—meningioma	8.07e-05	0.000132	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PDGFB—meningioma	8.06e-05	0.000132	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PDGFB—meningioma	8.04e-05	0.000132	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—AKT1—meningioma	7.98e-05	0.000131	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TSHB—meningioma	7.82e-05	0.000128	CbGpPWpGaD
Sorafenib—FGFR1—Disease—ERBB2—meningioma	7.71e-05	0.000127	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—ERBB2—meningioma	7.69e-05	0.000126	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TSHB—meningioma	7.63e-05	0.000125	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—meningioma	7.63e-05	0.000125	CbGpPWpGaD
Sorafenib—BRAF—Disease—PTEN—meningioma	7.61e-05	0.000125	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HES1—meningioma	7.54e-05	0.000124	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—ERBB2—meningioma	7.53e-05	0.000124	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—ERBB2—meningioma	7.5e-05	0.000123	CbGpPWpGaD
Sorafenib—KIT—Immune System—PTEN—meningioma	7.5e-05	0.000123	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—PTEN—meningioma	7.5e-05	0.000123	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—AKT1—meningioma	7.46e-05	0.000122	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—AKT1—meningioma	7.43e-05	0.000122	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—AKT1—meningioma	7.43e-05	0.000122	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—meningioma	7.42e-05	0.000122	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—AKT1—meningioma	7.38e-05	0.000121	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—ERBB2—meningioma	7.34e-05	0.00012	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALAD—meningioma	7.3e-05	0.00012	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—AKT1—meningioma	7.26e-05	0.000119	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PDGFB—meningioma	7.24e-05	0.000119	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TSHB—meningioma	7.19e-05	0.000118	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TSHB—meningioma	7.13e-05	0.000117	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—AKT1—meningioma	7.13e-05	0.000117	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—AKT1—meningioma	7.13e-05	0.000117	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—meningioma	7.13e-05	0.000117	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—PTEN—meningioma	7.12e-05	0.000117	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—PTEN—meningioma	7.1e-05	0.000117	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—AKT1—meningioma	7.05e-05	0.000116	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—AKT1—meningioma	7.03e-05	0.000115	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—ERBB2—meningioma	6.93e-05	0.000114	CbGpPWpGaD
Sorafenib—KIT—Disease—PTEN—meningioma	6.93e-05	0.000114	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PDGFB—meningioma	6.9e-05	0.000113	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—AKT1—meningioma	6.77e-05	0.000111	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—AKT1—meningioma	6.75e-05	0.000111	CbGpPWpGaD
Sorafenib—RAF1—Immune System—ERBB2—meningioma	6.69e-05	0.00011	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PTEN—meningioma	6.58e-05	0.000108	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PTEN—meningioma	6.56e-05	0.000108	CbGpPWpGaD
Sorafenib—CDK7—Gene Expression—AKT1—meningioma	6.52e-05	0.000107	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HES1—meningioma	6.51e-05	0.000107	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PDGFB—meningioma	6.45e-05	0.000106	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	6.45e-05	0.000106	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PTEN—meningioma	6.42e-05	0.000105	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—meningioma	6.42e-05	0.000105	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PTEN—meningioma	6.4e-05	0.000105	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—AKT1—meningioma	6.39e-05	0.000105	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—AKT1—meningioma	6.33e-05	0.000104	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—ERBB2—meningioma	6.31e-05	0.000104	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—AKT1—meningioma	6.27e-05	0.000103	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PTEN—meningioma	6.26e-05	0.000103	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—ERBB2—meningioma	6.25e-05	0.000103	CbGpPWpGaD
Sorafenib—RAF1—Disease—ERBB2—meningioma	6.18e-05	0.000101	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TSHB—meningioma	6.09e-05	0.0001	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—AKT1—meningioma	6.08e-05	9.98e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—AKT1—meningioma	6.06e-05	9.94e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—AKT1—meningioma	6.02e-05	9.88e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PTEN—meningioma	5.91e-05	9.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PTEN—meningioma	5.7e-05	9.36e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—ERBB2—meningioma	5.69e-05	9.33e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—ERBB2—meningioma	5.69e-05	9.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—AKT1—meningioma	5.64e-05	9.26e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PDGFB—meningioma	5.57e-05	9.14e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—AKT1—meningioma	5.42e-05	8.89e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—AKT1—meningioma	5.42e-05	8.89e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—ERBB2—meningioma	5.4e-05	8.86e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—ERBB2—meningioma	5.39e-05	8.84e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PTEN—meningioma	5.38e-05	8.83e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—meningioma	5.36e-05	8.79e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PTEN—meningioma	5.33e-05	8.75e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTEN—meningioma	5.27e-05	8.64e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ERBB2—meningioma	4.85e-05	7.96e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PTEN—meningioma	4.85e-05	7.96e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PTEN—meningioma	4.85e-05	7.96e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—AKT1—meningioma	4.8e-05	7.87e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—meningioma	4.78e-05	7.85e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—AKT1—meningioma	4.77e-05	7.82e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TSHB—meningioma	4.7e-05	7.72e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ERBB2—meningioma	4.63e-05	7.59e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTEN—meningioma	4.6e-05	7.55e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTEN—meningioma	4.59e-05	7.53e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTEN—meningioma	4.53e-05	7.44e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTEN—meningioma	4.53e-05	7.44e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKT1—meningioma	4.39e-05	7.2e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—meningioma	4.38e-05	7.19e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—meningioma	4.36e-05	7.16e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—meningioma	4.32e-05	7.1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—meningioma	4.32e-05	7.1e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ERBB2—meningioma	4.32e-05	7.1e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—meningioma	4.27e-05	7.01e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—meningioma	4.24e-05	6.95e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTEN—meningioma	4.14e-05	6.79e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—meningioma	4.1e-05	6.73e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—meningioma	4.09e-05	6.72e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—meningioma	3.99e-05	6.55e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTEN—meningioma	3.95e-05	6.47e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—meningioma	3.85e-05	6.32e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTEN—meningioma	3.85e-05	6.31e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTEN—meningioma	3.81e-05	6.26e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—meningioma	3.79e-05	6.22e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—meningioma	3.78e-05	6.2e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—meningioma	3.73e-05	6.12e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—meningioma	3.73e-05	6.12e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—meningioma	3.7e-05	6.07e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—meningioma	3.69e-05	6.05e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—meningioma	3.69e-05	6.05e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—meningioma	3.67e-05	6.02e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—meningioma	3.64e-05	5.97e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—meningioma	3.61e-05	5.92e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—meningioma	3.6e-05	5.9e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—meningioma	3.42e-05	5.61e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—meningioma	3.41e-05	5.59e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—meningioma	3.31e-05	5.43e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—meningioma	3.31e-05	5.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—meningioma	3.29e-05	5.39e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—meningioma	3.18e-05	5.22e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—meningioma	3.14e-05	5.16e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—meningioma	3.13e-05	5.14e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—meningioma	3.11e-05	5.1e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—meningioma	3.1e-05	5.09e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—meningioma	3.07e-05	5.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—meningioma	3.04e-05	4.98e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—meningioma	2.82e-05	4.63e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—meningioma	2.82e-05	4.63e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—meningioma	2.8e-05	4.59e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—meningioma	2.8e-05	4.59e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—meningioma	2.76e-05	4.52e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—meningioma	2.69e-05	4.42e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—meningioma	2.65e-05	4.35e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—meningioma	2.65e-05	4.34e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—meningioma	2.61e-05	4.29e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—meningioma	2.61e-05	4.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—meningioma	2.52e-05	4.13e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—meningioma	2.39e-05	3.92e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—meningioma	2.38e-05	3.91e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—meningioma	2.27e-05	3.73e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—meningioma	2.22e-05	3.64e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—meningioma	2.2e-05	3.61e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—meningioma	2.17e-05	3.56e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—meningioma	2.13e-05	3.5e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—meningioma	2.13e-05	3.49e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—meningioma	2.08e-05	3.41e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—meningioma	1.96e-05	3.22e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—meningioma	1.94e-05	3.19e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—meningioma	1.83e-05	3.01e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—meningioma	1.66e-05	2.72e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—meningioma	1.63e-05	2.67e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—meningioma	1.59e-05	2.61e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—meningioma	1.38e-05	2.26e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—meningioma	1.28e-05	2.1e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—meningioma	1.23e-05	2.01e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—meningioma	1.2e-05	1.97e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—meningioma	1.13e-05	1.85e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—meningioma	1.12e-05	1.84e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—meningioma	9.57e-06	1.57e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—meningioma	7.39e-06	1.21e-05	CbGpPWpGaD
